Clinical use of ibogaine

1. Clinical use of ibogaine Given most often for opiate detoxification, and also for dependence on other drugs such as methamphetamine and cocaine. Typically administered as a single oral dose in the range of 10 to 25 mg/kg of body weight. Advantages attributed by those who have been treated with ibogaine are higher tolerability relative to other standard treatments for acute opioid withdrawal, and post-treatment interval of diminished drug craving that may last days to month. Low dose protocols involving repeated administration of 10 to 50 mg/day are becoming increasingly common particularly for the treatment of stimulant dependence.

2. Evidence for effectiveness

3. Reports from people who have taken ibogaine: medical ethnography Consistency among reports of treatment experiences and outcomes The strongest attribution of efficacy is for the indication of acute opioid detoxification. Variable interval of reduced drug craving following treatment, often on the order of weeks to months The reports of individuals who have taken ibogaine may have mechanistic significance; e.g. descriptions of panoramic memory and “oneiric” state.

4. Published Ibogaine Case Studies • One paper describing 33 treatments for opioid dependence; complete resolution of withdrawal signs in 29 (88%)1. • Open label prospective study in St. Kitts N=32. Rating scales indicating resolution of withdrawal signs and symptoms at 24 hours, sustained improvement in depression scale scores at 1 month2. • 3 treatments, one for opioid dependence (Luciano et al. 1998) 1. Alper, KR, Lotsof, HS, Frenken, GMN, Luciano, DJ, and Bastiaans, J (1999). Treatment of Acute Opioid Withdrawal with Ibogaine. American Journal on Addictions 8: 234-242.2. Mash DC, Kovera CA, Pablo J, Tyndale R, Ervin FR, Kamlet JD, et al. Ibogaine in the treatment of heroin withdrawal. Alkaloids Chem Biol. 2001;56:155-71. 3. Luciano, DJ. (1998). Observations on treatment with Ibogaine. American Journal on Addictions 7, 89-90.

5. Post-treatment outcomes Table: Self-reported abstinence from the drug for which treatment had been sought following a total of 52 ibogaine treatments. This data influenced NIDA’s decision to begin its ibogaine project. Table from Alper, K.R., Lotsof, H.S., 2007. The use of ibogaine in the treatment of addictions. In: Winkelman, M., Roberts, T. (Eds.), Psychedelic Medicine. Praeger/Greenwood Publishing Group, Westport, CT, pp. 43-66.

6. June 1962. A heroin dependent lay drug experimenter serendipitously experiences the resolution of withdrawal following the use of ibogaine.

7. The nexus of harm reduction and ibogaine Nico Adriaans (1958-1995) • Nico Adriaans was active in a network of Dutch heroin users involved in ibogaine treatment. • Adriaans founded and led the "Rotterdamse Junkiebond”, the first drug users union. • The Junkiebond greatly influenced Dutch drug policy towards adopting the harm reduction model.It initiated the first needle exchange in Rotterdam in 1981, as well as other harm reduction interventions. • Not a “hippie”, a term which denotes irresponsibility and hedonism

9. Major statistical findings regarding the ibogaine subculture • The number of people who took ibogaine increased four-fold between 2001 and 2006 to an estimated total of 4,300- 4,900. • 68% took ibogaine for substance-related disorders. • 53% took ibogaine specifically for the treatment of opioid withdrawal; i.e., detoxification from typically high levels of physical dependence on opioids such as heroin and oxycontin

10. Opioid dependence is the central clinical focus of the ibogaine subculture Graphic by an Amsterdam squatter for the International Coalition for Addict Self-Help, a group of Dutch Heroin users involved in ibogaine treatments.

11. Left panel from triptych “Rise and Fall of Addiction” by Geerte Frenken

12. Ibogaine in the animal model

13. “All models are wrong, some models are useful”- George E. P. Box

14. Ibogaine in the animal modelMorphine withdrawal, an animal model of detoxification • A model of opioid detoxification based on the reduction of naloxone-precipitated withdrawal signs in a morphine-dependent rat. • Ibogaine reduced naloxone-precipitated opiate withdrawal in 11 independent replications in 3 different animal species: the rat, mouse and primate.

15. US patent for use of ibogaine to reduce opioid analgesic tolerance, Ciba Pharmaceutical Corp.,1957

16. In animals, reduced drug self-administration in following ibogaine treatment has been reported for • Morphine • Cocaine • Amphetamine • Nicotine • Alcohol

17. How does it work?

18. Placebo?

19. Placebo responder ?

20. The published literature indicates no clinically significant placebo effect in opioid detoxification. • Very few published clinical studies of opioid detoxification involving the three major treatments (methadone, buprenorphine, clonidine) even have a placebo condition. • In these few studies that did include placebo, the placebo group had significantly greater signs of withdrawal and dropped out of the study more often versus any active treatment.

21. There is no clinically significant placebo effect in opioid detoxification. Clinical example: • Go to Newark, West Baltimore, or the Bronx. • Sell a dummy bag of baking soda and maltose. • Return to the same location the following day. • See how long you live.

22. Is ibogaine working as an opioid agonist?

23. Evidence against ibogaine as an opioid agonist substitute: • Individuals who are successfully detoxified with a single dose of ibogaine do not go back into withdrawal. • Doses of ibogaine, given to non-dependent individuals, which may be higher than those used to treat opioid withdrawal, do not produce opioid overdose. (In this regard, consider that LD50 of methadone is 40 mg, whereas dosages of 80 mg/day are often used in opioid substitution maintenance.) • Ibogaine and noribogaine lack some properties expected of a  agonist, such as analgesia, but do potentiate opioid analgesics.

24. Opiate receptor Cell surface Cell interior

25. Signal transmission through the opiate receptor causes opiate effects such as euphoria or the “high” or reduction of pain

26. Opiates, or opiate receptor agonists bind to the opiate receptor and increase signal transmission through the receptor µ$ Opiate agonist Examples of opiate agonists include: • From the opium poppy: heroin, morphine • Synthetic: methadone, oxycontin, fentanyl • Naturally occurring in the body: endorphins  

27. Opiate receptor antagonists bind to the opiate receptor and block signal transmission through the receptor Opiate antagonist X Examples of opiate antagonists include: • Naloxone (short acting) • Naltrexone (long acting) 

28. Transmission through opiate receptors is reduced in the dependent state due to the development of tolerance Normal Dependent / tolerant  

29. Ibogaine reverses opiate tolerance/ dependence, possibly by changing the signaling through the receptor Pretreatment Dependent / tolerant Post-treatment  

30. Ibogaine might increase signal transmission through opiate receptors by an effect that is independent of substitute/agonist binding to the receptor. Pretreatment Dependent / tolerant Post-treatment CHANGE   This is a very important scientific possibility that could lead to fundamentally new treatment, and to a better understanding of the biological basis of addiction.

31. WE DON’T KNOW

32. Risks

33. Clinical features of fatalities that have occurred within 72 hours of the ingestion of ibogaine • Significant preexisting medical, particularly cardiac disease (e.g recent MI, cardiomyopathy), with bradyarrhythmia and/or possible QTc prolongation as possible mechanisms • At least one death has involved alcohol withdrawal seizures, which are dangerous on their own, and also contribute to cardiac risk due QT prolongation. Ibogaine will not prevent seizures due to withdrawal from benzodiazepines or alcohol. • Pulmonary embolism (PE), related to risk factors such as travel, immobility within a treatment, or generally increased liability towards thromboembolic events in IVDUs • Use of opiates or stimulants during a treatment due to potentiation of toxicity • Use of indigenous forms of uncertain origin and composition such as root bark or various extracts by the inexperienced and uninformed

34. The prevailing of true intention over obsession… is both a cardinal spiritual goal and a desired outcome of pharmacological treatment of addiction.